AstraZeneca is global innovation-driven biopharmaceutical company specialising in the discovery, development, manufacturing and marketing of prescription medicines that make a meaningful difference in healthcare. AstraZeneca discovers new medicines that are designed to improve the health and quality of life of patients around the world - medicines which are innovative, effective and which offer added benefits such as reduced side effects or better ways of taking the treatment. They also focus on getting the best from every medicine they make by exploring all the ways it can be used or improved. Their business strategy sets out their path to success in delivering great medicines to patients through innovative science and global excellence in development and commercialisation.
Type
Public
HQ
Cambridge, GB
Founded
1999
Size (employees)
59,700 (est)
AstraZeneca was founded in 1999 and is headquartered in Cambridge, GB
Report incorrect company information

Key People/Management at AstraZeneca

Leif Johansson

Leif Johansson

Non-Executive Chairman of the Board
Pascal Soriot

Pascal Soriot

Executive Director and Chief Executive Officer
Marc Dunoyer

Marc Dunoyer

Executive Director and Chief Financial Officer
Rudy Markham

Rudy Markham

Senior Independent Non-Executive Director
Genevieve Berger

Genevieve Berger

Non-Executive Director
Philip Broadley

Philip Broadley

Non-Executive Director
Show more

AstraZeneca Office Locations

AstraZeneca has offices in Wilmington, Colorado Springs, London, Cambridge and in 166 other locations
Shanghai, CN
43/F CITIC Square, 1168 Nan Jing Xi Road
Wedel, DE
Wedel, Tinsdaler Weg 183
Hong Kong, HK
18/F, Shui On Centre, 6-8 Harbour Road, Wanchai
Bangalore, IN
Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road
Osaka, JP
Grand Front Osaka Tower B, 3-1, Ofuka-cho, Kita-ku
London, GB
15 Stanhope Gate
Show all (171)
Report incorrect company information

AstraZeneca Financials and Metrics

AstraZeneca Financials

AstraZeneca's revenue was reported to be $21.32 b in FY, 2016 which is a 9.8% decrease from the previous period.
USD

Revenue (FY, 2016)

21.3 b

Revenue growth (FY, 2015 - FY, 2016), %

(9.8%)

Gross profit (FY, 2016)

17.2 b

Gross profit margin (FY, 2016), %

80.6%

Net income (FY, 2016)

3.4 b

Market capitalization (23-May-2018)

93.3 b

Closing share price (23-May-2018)

36.8

Cash (31-Dec-2016)

3.9 b
AstraZeneca's current market capitalization is $93.3 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

25.7 b26.1 b23.6 b21.3 b

Revenue growth, %

1%(9%)(10%)

Cost of goods sold

5.3 b5.8 b4.6 b4.1 b

Gross profit

20.5 b20.3 b19 b17.2 b
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Cash

6.1 b4.7 b4.6 b3.9 b

Accounts Receivable

3.6 b3.5 b3.4 b2 b

Current Assets

13.2 b12.2 b11.7 b10.1 b

PP&E

6.4 b7 b7.2 b8 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash From Operating Activities

7.4 b7.1 b3.3 b4.1 b

Cash From Financing Activities

(2 b)(2 b)649.3 m1.7 b

Income Taxes Paid

(457.7 m)(8.1 m)(179.7 m)(113.1 m)
USDY, 2016

Financial Leverage

4.2 x
Show all financial metrics

AstraZeneca Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016

Health Facilities Activated

250 403

Phase I Trials Products

33 24 44 41

Projects in R&D Pipeline

99 133 146 132

Young Health Programme Members

1.40 m1.60 m
Show all operating metrics
Report incorrect company information

AstraZeneca News and Updates

Oral Controlled Release Drug Delivery Technology Market is further Estimated to Reach Nearly US$ 50,000 Mn by 2027-end

North America to Remain the Largest Market for Oral Controlled Release Drug Delivery Technology Posted via Industry Today. Follow us on Twitter @IndustryToday

Neuropsychiatric Disorders and Treatment Industry Dynamics 2018 to 2023; Splendorous Growth at A CAGR Of 6.2% | Vital Players | By Disorders Degenerative Diseases, Neurotic Disorders, etc.

Worldwide “Neuropsychiatric Disorders and Treatment Market” 2018 to 2021 Research Report implements an exhaustive study on Market Research Future. The Neuropsychiatric Disorders and Treatment market has represented a huge scope for opportunities in the innovation of beauty devices. This Report Cover…

DNA Gyrase Subunit B (EC 5.99.1.3) Market – A comprehensive study by Key Players: Abgentis, AstraZeneca Plc, Daiichi Sankyo

Stay up-to-date with Gyrase Subunit B (EC 5.99.1.3) Market offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth. Posted via Industry Today. Follow us on Twitter @IndustryToday

AstraZeneca potassium drug finally approved, threatening Vifor

LONDON, May 21 (Reuters) - The decision by U.S. regulators to finally approve AstraZeneca's much-delayed excess potassium drug Lokelma gives the group another new medicine launch, boosting its portfolio as it strives to offset declining sales of older products.

TV scientists star in AstraZeneca's first ad campaign for asthma biologic Fasenra

An ad within an ad is the theme of AstraZeneca’s first DTC campaign for Fasenra. In the recently begun TV commercial, scientists on TV talk about eosinophilic asthma while potential patients watch the “show” and react as they go about their daily lives.
Show more
Report incorrect company information